Bristol-Myers Squibb Co. (BMY)

48.98
0.21 0.43
NYSE : Health Technology
Prev Close 49.19
Open 49.13
Day Low/High 48.73 / 49.23
52 Wk Low/High 44.30 / 68.22
Volume 3.97M
Avg Volume 18.31M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 80.97B
EPS 3.00
P/E Ratio 16.48
Div & Yield 1.64 (3.23%)

Latest News

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Caterpillar's 'High-Water Mark' Comment in 2018 Puts Finer Focus on 2019 Outlook

Caterpillar's 'High-Water Mark' Comment in 2018 Puts Finer Focus on 2019 Outlook

Management commentary from CAT is key on Monday.

What Fools We All Have Become, and Buying Lam Research: Market Recon

What Fools We All Have Become, and Buying Lam Research: Market Recon

Replacing fear with pragmatism, that is our goal.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman is top of the heap for takeovers.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Try This Allergan Two-Week Setup

Try This Allergan Two-Week Setup

The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Searching for Signs of Bottoming Action

Searching for Signs of Bottoming Action

The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.

Jim Cramer: What to Buy in This Treacherous Market

Jim Cramer: What to Buy in This Treacherous Market

Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Consider These Diagnostic Testing Firms

Consider These Diagnostic Testing Firms

Diagnostic firms can have an advantage of recurring revenue streams.

Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Let's take a fresh look at the charts.